Brief Acceptance and Commitment Therapy for HIV-infected At-risk Drinkers

Treatment Clinical Trial

Official title:

Brief Acceptance and Commitment Therapy for HIV-infected At-risk Drinkers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03974061
• Other study ID #: 17-278
• Status: Completed
• Phase: N/A
• Start date: November 1, 2019
• Est. completion date: November 10, 2022

Study information

• Verified date: October 2023
• Source: Syracuse University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Alcohol consumption at hazardous levels is associated with negative consequences on nearly every step of the HIV care continuum. It is a critical factor in HIV treatment that, if unaddressed, significantly contributes to onward transmission and poor treatment outcomes. Alcohol interventions for people living with HIV (PLWH) in the United States (US) have shown mixed results, and no alcohol intervention for PLHW has shown long-term reductions in heavy drinking or a significant impact on HIV-related outcomes. One hypothesized reason for this limited success is the failure of these interventions to address the multiple overlapping problems (e.g., comorbid mental health conditions, behavioral health needs) of PLWH who are hazardous drinkers. Innovative alcohol intervention strategies that can have an impact on these multiple behavioral health needs, in a format that can be feasibly delivered in the context of HIV care, are needed. Brief Acceptance and Commitment Therapy (ACT) is a promising intervention for HIV-infected hazardous drinkers. ACT is a transdiagnostic treatment that uses mindfulness skills and values-guided behavioral action plans to impact a broad array of psychological symptoms. ACT has shown efficacy for treatment of anxiety, depression, chronic pain, and substance use, making it a promising approach for hazardous drinkers. The overall objective of this application is to adapt an existing brief ACT intervention developed for smoking cessation, and pilot test its feasibility and acceptability for PLWH who are hazardous drinkers. We hypothesize that the resulting intervention will be preliminarily associated with decreased alcohol use, improved ART adherence, decreased symptoms of depression, anxiety, and drug use, and increased acceptance-a known mechanism of change in ACT.

Description:

Alcohol use is a major problem in HIV care. Sixty-six percent of people living with HIV (PLWH) report using alcohol in the previous year, 8-20% report drinking at hazardous or heavy levels, and 30% report current binge drinking (>5 drinks in an occasion in the past 30 days). PLWH who are hazardous drinkers, compared to those who abstain, experience a significant increased risk for: taking ART medications off schedule, suboptimal adherence to ART, and engaging in sexual risk behavior. Hazardous alcohol consumption has been found to affect every stage of the HIV care continuum, from diagnosis, to linkage to care, to retention, and viral suppression, making it a critical factor in HIV treatment that, if unaddressed, may significantly contribute to onward transmission.

Behavioral interventions for HIV-infected drinkers have provided limited evidence of benefit. HIV-prevention interventions do not typically address alcohol use, and it is often overlooked in HIV care. While there have been several clinical trials of alcohol interventions for PLWH in the US, these trials have shown mixed results for reducing alcohol use and improving HIV-related outcomes. No alcohol intervention for PLHW has shown long-term reductions in heavy drinking or a significant impact on HIV-related outcomes. One hypothesized reason for this limited success is that PLWH who are at-risk drinkers are also likely to have multiple overlapping problems. It is estimated that 38% of PLWH meet criteria for both a substance use and another psychiatric disorder and also have a myriad of behavioral health needs (e.g., treatment adherence, condom use), any one of which would benefit from intervention. In order to adequately address these issues, PLWH require innovative alcohol intervention strategies that can also have an impact on other behavioral and mental health needs, in a format that can be feasibly delivered in the context of HIV care.

Brief acceptance and commitment therapy (ACT) is a promising intervention for HIV-infected drinkers. ACT is a transdiagnostic treatment that targets experiential avoidance (repeated attempts to eliminate or avoid difficult thoughts/feelings) as an underlying factor common to mental and behavioral health problems. Mindfulness skills and values-guided behavioral action plans are used to decrease experiential avoidance and impact a broad array of psychological symptoms. ACT has shown efficacy for treatment of anxiety depression, and chronic pain, making it a promising approach for HIV-infected hazardous drinkers. A recently published meta-analysis also indicates that ACT is efficacious for smoking, opiate use, methamphetamine use, and polydrug abuse, showing a small to medium effect size compared to active treatment controls (e.g., Cognitive Behavioral Therapy (CBT), pharmacotherapy). ACT's unique focus on skills that increase the ability to experience and accept, rather than change and control, urges and cravings related to substance use is different from more traditional forms of addiction treatment such as CBT. Indeed, a pilot RCT of a brief, telephone-delivered ACT intervention for smoking cessation had quit rates more than double that of traditional CBT for smokers with comorbid depression. However, ACT has not been studied as an intervention for hazardous drinkers.

The overall objective of this study is to adapt an existing brief ACT intervention and pilot test its feasibility, acceptability, and preliminary efficacy for PLWH who are hazardous drinkers. We hypothesize that the resulting intervention will have a significant effect on biological and self-reported measures of alcohol use and ART adherence. Secondary analyses will also examine changes in acceptance-a known mechanism of change in ACT -symptoms of depression and anxiety, and drug use, which we expect to differ by treatment group. The specific aims are as follows:

Aim 1: Adapt an existing brief ACT intervention for HIV-infected at-risk drinkers (ACT). We will accomplish this aim by: Modifying an existing 5-session, telephone-delivered ACT intervention for smoking cessation using a theoretical framework that has been previously used to systematically adapt evidence-based HIV interventions. We will conduct iterative multidisciplinary team meetings, focus group discussions with HIV clinic patients (N = 15-20), and qualitative interviews with HIV clinic providers (N = 5-10) to inform the adaptation process, get feedback on intervention content, and develop a new treatment manual.

Aim 2: Conduct a pilot superiority trial of ACT compared to a brief alcohol intervention. We will accomplish this aim by: Randomly assigning N = 74 HIV-infected hazardous drinkers (50% women) to the intervention developed in Aim 1 (n = 30) or a brief alcohol intervention previously developed for PLWH that is nearly equivalent in number and length of sessions. We will assess feasibility, acceptability, and primary trial outcomes of alcohol use and ART adherence immediately post-treatment and again at 3 and 6-months post-randomization. Secondary outcomes of changes in acceptance, symptoms of depression, symptoms of anxiety, and drug use will be assessed at all time points.

The proposed research will provide essential pilot data for an R01 application to conduct a full-scale RCT to determine the efficacy of ACT compared with the current evidence-based treatment for PLWH. If successful, this intervention will have broad implications for implementation in HIV and other integrated care settings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: November 10, 2022
• Est. primary completion date: November 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. =18 years of age,

2. HIV-positive,

3. currently prescribed ART medication,

4. score of =4 (men) or =3 (women) on the AUDIT-C.

Exclusion Criteria:

1. Experiencing acute illness or declining health status when it is determined by a treatment provider that research participation is contraindicated,

2. unable to understand spoken English,

3. does not own a cell phone,

4. a score of 12 on the AUDIT-C, indicating high risk for a severe alcohol use disorder,

5. a score of =20 on the PHQ-9 indicating severe depressive symptoms,

6. a score of =15 on the GAD-7, indicating severe symptoms of anxiety,

7. experiencing active psychosis as judged by research staff via scores on the BSI.

Related Conditions & MeSH terms

• Treatment

Intervention

Behavioral:
• Brief Acceptance and Commitment Therapy
Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
• Brief Alcohol Intervention
The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.

Locations

Country	Name	City	State
United States	Syracuse University	Syracuse	New York

Sponsors (1)

Lead Sponsor	Collaborator
Syracuse University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Chronic Pain	Pain will be measured using the total score obtained via the self-report brief Graded Chronic Pain Scale (GCPS-PCS). The GCPS-CPS is a 3-item measure that yields both continuous and categorical outcomes of pain.	Pain will be measured at baseline, 7-weeks post-baseline, 3 and 6-month follow-ups.
Other	HIV Medication Adherence Self-Efficacy	HIV Medication Adherence Self-Efficacy will be measured using the total score obtained via the self-report HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). The HIV-ASES is a 12-item measure of one's confidence in their ability to adhere to a treatment plan.	HIV Medication Adherence Self-Efficacy will be measured at baseline, 7-weeks post-baseline, 3 and 6-month follow-ups.
Other	Alcohol-Related Problems	Alcohol-related problems will be measured using the total score obtained from the Short Inventory of Problems (SIP-2L). The SIP-2L is a 15-item measure that assesses negative consequences of alcohol use.	Alcohol-related problems will be measured at baseline, 7-weeks post-baseline, 3 and 6-month follow-ups.
Primary	Change in alcohol consumption from baseline to 7-weeks post-treatment	Alcohol consumption will be measured by retrospective self-report via the Time Line Follow Back (TLFB) interview method which yields the following: number of drinks per drinking day, number of heavy drinking (>3 for women; >4 for men) episodes, and number of drinking days over the last 42-day period.	Change in alcohol consumption will be measured via the TLFB from baseline to end of treatment at 7-weeks.
Primary	Change in alcohol consumption from 7-weeks post-treatment to 3-months post-baseline	Alcohol consumption will be measured by retrospective self-report via the Time Line Follow Back (TLFB) interview method which yields the following: number of drinks per drinking day, number of heavy drinking (>3 for women; >4 for men) episodes, and number of drinking days over the last 42-day period.	Change in alcohol consumption will be measured via the TLFB from 7-weeks post-treatment to 3-months post-baseline.
Primary	Change in alcohol consumption from 3-months post-baseline to 6-months post-baseline	Alcohol consumption will be measured by retrospective self-report via the Time Line Follow Back (TLFB) interview method which yields the following: number of drinks per drinking day, number of heavy drinking (>3 for women; >4 for men) episodes, and number of drinking days over the last 42-day period.	Change in alcohol consumption will be measured via the TLFB from 3-months post-baseline to 6-months post-baseline.
Primary	Change in alcohol consumption from baseline to 6-months post-baseline	Alcohol use will also be assessed using the biomarker phosphatidylethanol (PEth). PEth is an abnormal phospholipid formed only in the presence of alcohol with an estimated half-life of 4-12 days and can be measured from dried blood spots.	Change in alcohol consumption will be measured via PEth from baseline to 6-months post-baseline.
Primary	Change in ART adherence from baseline to 7-weeks post-treatment	Adherence will be measured by self-report via the validated visual analog scale (VAS) to identify participants will optimal (>95%) versus suboptimal (<95%) adherence. The VAS asks participants to point to the place on a line ranging from 0-100% that best represents how much of their ART medication that they have taken in the last month.	Change in ART adherence will be measured via VAS from baseline to end of treatment at 7-weeks.
Primary	Change in ART adherence from 7-weeks post-treatment to 3-months post-baseline	Adherence will be measured by self-report via the validated visual analog scale (VAS) to identify participants will optimal (>95%) versus suboptimal (<95%) adherence. The VAS asks participants to point to the place on a line ranging from 0-100% that best represents how much of their ART medication that they have taken in the last month.	Change in ART adherence will be measured via VAS from 7-weeks post-treatment to 3-months post-baseline.
Primary	Change in ART adherence from 3-months post-baseline to 6-months post-baseline	Adherence will be measured by self-report via the validated visual analog scale (VAS) to identify participants will optimal (>95%) versus suboptimal (<95%) adherence. The VAS asks participants to point to the place on a line ranging from 0-100% that best represents how much of their ART medication that they have taken in the last month.	Change in ART adherence will be measured via VAS from 3-months post-baseline to 6-months post-baseline.
Primary	Change in ART adherence from baseline to 6-months post-baseline	Adherence will also be measured via ARV levels in hair. Hair concentrations of ARVs have been shown to be the strongest independent predictor of virological success in prospective cohorts of HIV-infected patients.	Change in ART adherence will be measured via ARV levels in hair from baseline to 6-months post-baseline.
Secondary	Acceptance	Acceptance will be measured using the total score obtained via the self-report Brief Experiential Avoidance Questionnaire (BEAQ). The BEAQ is a 15-item measures that assesses six domains of experiential avoidance: behavioral avoidance, distress aversion, procrastination, distraction, repression/denial and distress endurance.	Acceptance will be measured at baseline, 7-weeks post-baseline, and 3 and 6-month follow-ups.
Secondary	Symptoms of Depression	Symptoms of depression will be measured using the total score obtained via the self-report Patient Health Questionnaire (PHQ)-9. The PHQ-9 is a 10-item standardized measure of depression severity.	Symptoms of depression will be measured at baseline, 7-weeks post-baseline, and 3 and 6-month follow-ups.
Secondary	Symptoms of Anxiety	Symptoms of anxiety will be measured using the total score obtained via the self-report Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 is a 7-item standardized measure of anxiety severity.	Symptoms of anxiety will be measured at baseline, 7-weeks post-baseline, 3 and 6-month follow-ups.
Secondary	Substance Use	Substance use will be measured by retrospective self-report via the Time Line Follow Back (TLFB) interview method which yields the number of days non-prescription drugs were used.	Substance use will be measured at baseline, 7-weeks post-baseline, and 3 and 6-month follow-ups